Viking Therapeutics (NASDAQ: VKTX) soared into the spotlight about a year ago when it delivered promising data on a drug ...

Lilly’s new products also contributed ... of 3.5% for the industry. Image Source: Zacks Investment Research Lilly’s tremendous success with Mounjaro and Zepbound made it the biggest drugmaker ...

Wave goodbye to the Part D "donut hole" and hello to a $2,000 cap on the amount you'll pay for medications. But other changes ...

“There are medications that work, but they’re priced for profits, not patients,” says the narrator, as images of bathroom ... cheaper version in a bind. Zepbound, another weight-loss drug ...

A telehealth company partnered with a pharmacy that lacked a required license, raising doubts about the safety and efficacy ...

US President Donald Trump launched his "fair and reciprocal" plan for trade last week [] Ireland's goods exports to the ...

Image Source: Zacks Investment Research NVO ... Quarterly revenues from sales of Rybelsus and certain insulin products are likely to have put up a strong performance in fourth-quarter 2024 ...

(Tirzepatide is the active ingredient in Eli Lilly's obesity drug Zepbound.) She'd been taking the drugs already ... them low ...

U.S. stock futures are edging mostly higher as investors watch corporate earnings, Honeywell plans to split into three ...

Eli Lilly LLY announced that it is increasing its manufacturing capacity in the United States by building four new plants.

Pharmaceutical giant Eli Lilly is once again expanding the supply of its weight-loss drug Zepbound and cutting the cost for patients that don't have insurance.